Vimarsana
Biggest News Aggregation in the World

Page 2 - Equitis Gestion News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Equitis Gestion. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Equitis Gestion Today - Breaking & Trending Today

Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th - Vimarsana News

Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th

DJ Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th

Pharnext executes a financing agreement with -5- - Vimarsana News

Pharnext executes a financing agreement with -5-

DJ Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A Pharnext Pharnext executes a financing agreement

Pharnext executes a financing agreement with -4- - Vimarsana News

Pharnext executes a financing agreement with -4-

DJ Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A Pharnext Pharnext executes a financing agreement

Pharnext executes a financing agreement with -2- - Vimarsana News

Pharnext executes a financing agreement with -2-

DJ Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A Pharnext Pharnext executes a financing agreement

Pharnext executes a financing agreement with -3- - Vimarsana News

Pharnext executes a financing agreement with -3-

DJ Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A Pharnext Pharnext executes a financing agreement